Table 3.
Relationships between expression of VEGFR-2,DGFR-β, and c-MET and prognosis in HCC patients who took sorafenib
| |
N |
PFS OS |
|||||
|---|---|---|---|---|---|---|---|
| Months | χ2 | P | months | χ2 | P | ||
|
PDGFR-β |
65 |
|
|
|
|
|
|
| High |
13 |
4.23 |
|
|
5.87 |
|
|
| Low |
52 |
5.60 |
1.345 |
0.246 |
8.97 |
3.996 |
0.046 |
|
VEGFR-2 |
65 |
|
|
|
|
|
|
| High |
58 |
4.97 |
|
|
7.40 |
|
|
| Low |
7 |
7.93 |
0.391 |
0.532 |
11.37 |
0.514 |
0.473 |
|
c-MET |
65 |
|
|
|
|
|
|
| High |
55 |
5.60 |
|
|
8.97 |
|
|
| Low | 10 | 1.43 | 6.558 | 0.010 | 6.47 | 0.930 | 0.335 |
VEGFR-2, vascular endothelial growth factor receptor-2; PDGFR-β, platelet-derived growth factor receptor-β; C-MET, hepatocyte growth factor receptor; PFS, progression-free survival; OS, overall survival.